• Inventiva to Participate in Upcoming September Investor Conferences

    Source: Nasdaq GlobeNewswire / 04 Sep 2025 13:00:00   America/Los_Angeles

    Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events: 

    H.C. Wainwright 27th Annual Global Investment Conference
    Date: Tuesday, September 9, 2025
    Time of the fireside chat: 3:00pm (EDT)/9:00pm (CEST)
    Location: New York, NY

    8th Edition of the Lyon Pôle Bourse Forum
    Date: Tuesday, September 23, 2025
    Location: Lyon, France

    KBC Life Sciences Conference 
    Date: Thursday, September 25, 2025
    Time of the presentation: 5:00am (EDT)/11:00am (CEST)
    Location: Brussels, Belgium

    Stifel 2025 Virtual Cardiometabolic Forum
    Date: Tuesday, September 30, 2025
    Time of the presentation: 9:30am (EDT)/3:30pm (CEST)
    Location: Virtual

    European MIDCAP Event 2025
    Date: Tuesday, September 30 - Wednesday, October 1, 2025
    Location: Paris, France

      

    About Inventiva

    Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

    Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). http://www.inventivapharma.com

    Contacts 

    Inventiva

    Pascaline Clerc

    EVP, Strategy and Corporate Affairs

    media@inventivapharma.com

       +1 202 499 8937
    ICR Healthcare

    Alexis Feinberg

    Media Relations

    inventivapr@icrhealthcare.com

    +1 203 939 2225


     


     
    ICR Healthcare

    Patricia L. Bank

    Investor Relations

    patti.bank@icrhealthcare.com  

    +1 415 513 1284

    Attachment


Share on,